BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10714751)

  • 1. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches.
    Fideleff HL; Boquete HR; Sequera A; Suárez M; Sobrado P; Giaccio A
    J Pediatr Endocrinol Metab; 2000 Mar; 13(3):261-7. PubMed ID: 10714751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Giant Prolactinomas.
    Shimon I
    Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current approach to treatments for prolactinomas.
    Tirosh A; Shimon I
    Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of prolactinomas: a ten-year experience.
    Merola B; Colao A; Panza N; Caruso E; Spaziante R; Schettini G; de Divitiis E; Pacilio G; Lombardi G
    Med Oncol Tumor Pharmacother; 1992; 9(2):93-9. PubMed ID: 1341722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and therapeutic aspects of prolactinoma in men].
    Braucks GR; Naliato EC; Tabet AL; Gadelha MR; Violante AH
    Arq Neuropsiquiatr; 2003 Dec; 61(4):1004-10. PubMed ID: 14762607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of prolactinoma].
    Serri O; Somma M; Beauregard H; Rasio E; Comtois R; Aris-Jilwan N; Boucher A; Hardy J
    Union Med Can; 1993; 122(6):496-9. PubMed ID: 7905686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of invasive giant prolactinomas.
    Yu C; Wu Z; Gong J
    Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactinomas in children and adolescents.
    Colao A; Loche S
    Endocr Dev; 2010; 17():146-159. PubMed ID: 19955764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of hypophyseal prolactin-secreting macroadenomas].
    Candrina R; Tosoni M
    Recenti Prog Med; 1989 Sep; 80(9):471-3. PubMed ID: 2595078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.